Browsing by Author "Oriabinska, L.B."

Now showing 1 - 3 of 3

Multistrain probiotic production by co-culture fermentation in a lab-scale bioreactor
(2016) Jangra, M.; Belur, P.D.; Oriabinska, L.B.; Dugan, O.M.
Most commercial probiotic products intended for pharmaceutical applications consist of combinations of probiotic strains and are available in various forms. The development of co-culture fermentation conditions to produce probiotics with the correct proportion of viable microorganisms would reduce multiple operations and the associated costs. The aim of this study was to develop a fermentation medium and process to achieve biomass comprising the desired proportion of two probiotic strains in co-culture. Initially, a quantification medium was developed, and the method was optimized to allow the quantification of each strain's biomass in a mixture. The specific growth rates of Lactobacillus delbrueckii spp. bulgaricus and Lactobacillus plantarum were determined in media with different carbon sources. The inoculum volume was optimized to achieve equal proportion of biomass in co-culture fermentation in test tubes. Next, fermentation was carried out in a 3-L bioreactor. A biomass concentration of 2.06 g/L, with L. delbrueckii spp. bulgaricus and L. plantarum in the ratio of 47%:53% (by weight), was achieved with concomitant production of 12.69 g/L of lactic acid in 14 h. The results show that with careful manipulation of process conditions, it is possible to achieve the desired proportion of individual strains in the final biomass produced by co-culture fermentation. This process may serve as a model to produce multistrain probiotic drugs at industrial scale. 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Multistrain probiotic production by co-culture fermentation in a lab-scale bioreactor
(Wiley-VCH Verlag info@wiley-vch.de, 2016) Jangra, M.; Belur, P.D.; Oriabinska, L.B.; Dugan, O.M.
Most commercial probiotic products intended for pharmaceutical applications consist of combinations of probiotic strains and are available in various forms. The development of co-culture fermentation conditions to produce probiotics with the correct proportion of viable microorganisms would reduce multiple operations and the associated costs. The aim of this study was to develop a fermentation medium and process to achieve biomass comprising the desired proportion of two probiotic strains in co-culture. Initially, a quantification medium was developed, and the method was optimized to allow the quantification of each strain's biomass in a mixture. The specific growth rates of Lactobacillus delbrueckii spp. bulgaricus and Lactobacillus plantarum were determined in media with different carbon sources. The inoculum volume was optimized to achieve equal proportion of biomass in co-culture fermentation in test tubes. Next, fermentation was carried out in a 3-L bioreactor. A biomass concentration of 2.06 g/L, with L. delbrueckii spp. bulgaricus and L. plantarum in the ratio of 47%:53% (by weight), was achieved with concomitant production of 12.69 g/L of lactic acid in 14 h. The results show that with careful manipulation of process conditions, it is possible to achieve the desired proportion of individual strains in the final biomass produced by co-culture fermentation. This process may serve as a model to produce multistrain probiotic drugs at industrial scale. © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Probiotic and biotherapeutic properties of tannase positive lactobacillus plantarum MTCC 2621 strain
(Media Sphera Publishing Group mediashp@mediasphera.ru 46, Dmitrovskoe Shosse, Build. 2, Floor 4, Moscow 127238, 2019) Oriabinska, L.B.; Prasanna, D.B.; Lazarenko, L.M.
The article presents the data on the probiotic properties of Lactobacillus plantarum MTCC 2621 strain obtained from the collection of microorganisms and the gene bank of the Institute of Microbial Technologies of India. The distinctive feature of the strain is its ability to produce tannase enzyme, which is connected with the antioxidant properties of the probiotic. It was shown that L.plantarum MTCC 2621 is antagonistic to Gram-positive and Gram-negative bacteria, as well as yeast. Its high potential for adhesion (IAM — 7.10±0.39) and selective resistance to a wide range of antibiotics (oxacillin, benzylpenicillin, gentamicin, kanamycin, enrofloxacin, polymyxin C and polymyxin M) were established. The immunological tolerance of the strain as well as its ability to stimulate nonspecific antiviral defense and innate immune system of the organism due to the activation of the synthesis of type I interferon were revealed in series of preclinical studies. The method of spectral-dynamic analysis shows the potential antitumor activity of L.plantarum MTCC 2621 against such oncological diseases as squamous and keratinized cervical cancer, uterine myoma, and cystic process. © 2019 Media Sphera Publishing Group. All rights reserved.